Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits

• Published in: World journal of clinical cases Vol. 9; no. 33; pp. 10172 - 10179
• Main Authors: Chen, Xiu, Zhao, Feng, Pan, Wei-Juan, Di, Jia-Mei, Xie, Wei-Nan, Yuan, Ling, Liu, Zhi
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 26.11.2021
• Subjects: Clinical Trials Study; Drug efficacy; Hemodialysis; Drug safety; Secondary hyperparathyroidism; Paricalcitol

Secondary hyperparathyroidism (SHPT) is a common complication in patients with end-stage renal disease and it is also common in hemodialysis patients. SHPT can increase bone fragility and calcification of blood vessels and soft tissues, which greatly increases the risk of death. To discuss the outco...